Clinical trial NCT05504213: A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
Official title: A Phase Ib, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10352 in Combination With Fulvestrant in Patients With Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2)-Negative, PIK3CA Mutation, Locally Advanced or Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Breast Cancer
Keywords: dose-escalation
dose-expansion
advanced breast cancer
hormone receptor positive
PIK3CA gene mutation
Lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2022-08-17
Enrollment: 224
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase (p110α). The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10352 plus fulvestrant in patients with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast cancer (ABC) harboring PIK3CA mutations.

Detailed description: This is a Phase Ib open-label, 2-Part, multi-center study in China. The study will be conducted in two stages: Stage 1 is the dose-escalation part, which is designed to evaluate the safety, tolerability, PK and efficacy, as well as to determine the maximum tolerable dosage (MTD) or maximum applicable dose (MAD) of HS-10352 in combination with fulvestrant. Stage 2 is the dose-expansion part, which is aimed to further assess the efficacy, safety, tolerability and PK, and to establish the recommended phase 2 dose (RP2D) of HS-10352 in combination with fulvestrant.

All participants will be carefully monitored for adverse events (AE) during the study treatment and for 28 days after the last dose of study drug. The PK characteristics of HS-10352 and fulvestrant will be evaluated from C1 to C6. Subjects of this study will be assessed for progression once every 8 weeks until objective disease progression or withdrawal from the trial. As the disease progresses, survival follow-up is recommended bimonthly.

Eligibility criteria: Inclusion Criteria:

1. Men or women aged more than or equal to (≥) 18 years
2. HR+ HER2- breast cancer confirmed by histology or cytology.
3. Locally advanced disease not amenable to curative treatment by surgery or metastatic disease.
4. Have adequate tumor tissue for the analysis of PIK3CA mutational status. At dose expansion stage, participants should be identified as PIK3CA-mutation positive before enrollment.
5. Females should have postmenopausal status due to either surgical/natural menopause or ovarian suppression with a luteinizing hormone releasing hormone (LHRH) agonist before enrollment. Males should be pre-treated with a LHRH agonist.
6. Have either measurable disease per RECIST v1.1 criteria or at least one predominantly lytic bone lesion must be present.
7. ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks.
8. Estimated life expectancy for at least three months
9. Females should be using adequate contraceptive measures and should not be breastfeeding at the time of screening, during the study and until 6 months after completion of the study; and have negative results of blood pregnancy test prior to C1D1.

   Males should be using adequate contraceptive measures at the time of screening, during the study and until 6 months after completion of the study.
10. Have signed Informed Consent Form
11. Dose escalation stage-Cohort 1: subjects resistant to endocrine therapy Dose expansion stage-Cohort 2: subjects resistant to endocrine therapy Dose expansion stage-Cohort 3: endocrine therapy-sensitive or endocrine-naive subjects

Exclusion Criteria:

1. Participant with symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the investigator's best judgment
2. Treatment with any of the following:

   1. Previous or current treatment with PI3K, AKT or mTOR inhibitors
   2. For expansion stage, prior treatment with fulvestrant
   3. Any cytotoxic chemotherapy, investigational agents within 21 days of the first dose of study drug; anticancer drugs which have been received within 14 days before the first administration.
   4. Radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.
   5. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.
3. With inflammatory breast cancer at screening.
4. Inadequate bone marrow reserve or organ function.
5. Uncontrolled pleural effusion or ascites or pericardial effusion.
6. Known and untreated, or active central nervous system metastases.
7. History of primary or secondary diabetes.
8. History of acute or chronic pancreatitis
9. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow the study drug that would preclude adequate absorption of HS-10352 or fulvestrant.
10. History of hypersensitivity to any active or inactive ingredient of HS-10352/ fulvestrant or to drugs with a similar chemical structure or class to HS-10352.
11. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
12. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.

Primary outcomes:
measure: [Stage 1] Maximum tolerated dose (MTD) of HS-10352 in combination with fulvestrant
timeFrame: Cycle 1 (28 days)
measure: [Stage 1] Maximum applicable dose (MAD) of HS-10352 in combination with fulvestrant
timeFrame: Cycle 1 (28 days)
measure: [Stage 2] Objective response rate (ORR) of HS-10352 in combination with fulvestrant
timeFrame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 3 years
Secondary outcomes:
measure: [Stage 1 and Stage 2] Incidence and severity of treatment-emergent adverse events
timeFrame: From Cycle 1 Day 1 (C1D1) until 28 days after the final dose. A cycle is 28 days.
measure: [Stage 1 and Stage 2] PK parameters: the maximum concentration (Cmax) of HS-10352
timeFrame: Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)
measure: [Stage 1] PK parameters: the maximum concentration (Cmax) of fulvestrant
timeFrame: Cycle 1 (28 days)
measure: [Stage 1 and Stage 2] PK parameters: time of the maximum concentration (Tmax) of HS-10352
timeFrame: Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)
measure: [Stage 1] PK parameters: time of the maximum concentration (Tmax) of fulvestrant
timeFrame: Cycle 1 (28 days)
measure: [Stage 1 and Stage 2] PK parameters: elimination half life (t1/2) of HS-10352
timeFrame: Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)
measure: [Stage 1 and Stage 2] PK parameters: area under the concentration-time curve over 24 hours (AUC0-24) of HS-10352
timeFrame: Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)
measure: [Stage 1 and Stage 2] PK parameters: area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t) of HS-10352
timeFrame: Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)
measure: [Stage 1] PK parameters: area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t) of fulvestrant
timeFrame: From Cycle 1 to Cycle 2， each cycle is 28 days
measure: [Stage 1 and Stage 2] PK parameters: the maximum concentration at steady-state (Css,max) of HS-10352
timeFrame: Cycle 2 Day 1 (C2D1)，at the first day of Cycle 2 (each cycle is 28 days) each cycle is 28 days
measure: [Stage 1] PK parameters: the maximum concentration at steady-state (Css,max) of fulvestrant
timeFrame: Cycle 2 (28 days)
measure: [Stage 1 and Stage 2] PK parameters: time of the maximum concentration at steady state (Tss,max) of HS-10352
timeFrame: Cycle 2 Day 1 (C2D1)，at the first day of Cycle 1 (each cycle is 28 days)
measure: [Stage 1] PK parameters: time of the maximum concentration at steady state (Tss,max) of fulvestrant
timeFrame: Cycle 2 (28 days)
measure: [Stage 1 and Stage 2] PK parameters: the minimum concentration at steady-state (Css,min) of HS-10352
timeFrame: Cycle 2 Day 1 (C2D1)，at the first day of Cycle 1 (each cycle is 28 days)
measure: [Stage 1 and Stage 2] PK parameters: the minimum concentration at steady-state (Css,min) of fulvestrant
timeFrame: Cycle 2 (28 days)
measure: [Stage 1] Efficacy of HS-10352 in combination with fulvestrant: ORR
timeFrame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 3 years
measure: [Stage 1 and Stage 2] Efficacy of HS-10352 in combination with fulvestrant: disease control rate (DCR)
timeFrame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 3 years
measure: [Stage 1 and Stage 2] Efficacy of HS-10352 in combination with fulvestrant: duration of response (DoR)
timeFrame: From the date of CR, PR until the date of disease progression or withdrawal from study, approximately 3 years
measure: [Stage 1 and Stage 2] Efficacy of HS-10352 in combination with fulvestrant: progression free survival (PFS)
timeFrame: From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or withdrawal from study, approximately 3 years
measure: [Stage 2] Efficacy of HS-10352 in combination with fulvestrant: overall survival (OS)
timeFrame: From the date of randomization or first dose (if randomization is not needed) until the documentation of death from any cause, approximately 6 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
affiliation: Fudan University
name: Xichun Hu, PhD
role: PRINCIPAL_INVESTIGATOR
References: